Association between the peroxisome proliferator-activated receptor γ pro12ala variant and haplotype and pancreatic cancer in a high-risk cohort of smokers: A pilot study

Pancreas

Volumn 38, Issue 6, 2009, Pages 631-637

  Fesinmeyer, Megan Dann ^a,b   Stanford, Janet L ^b,c   Brentnall, Teresa A ^d   Mandelson, Margaret T ^b,e   Farin, Federico M ^d   Srinouanprachanh, Sengkeo ^d   Afsharinejad, Zahra ^d   Goodman, Gary E ^b   Barnett, Matt J ^b   Austin, Melissa A ^a,b,c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c Department of Epidemiology ^*  (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e CENTER FOR HEALTH STUDIES   (United States)

Author keywords

Cigarette smoking; Pancreatic neoplasms; PPARG; Vitamin A

Indexed keywords

ALANINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLACEBO; PROLINE; RETINOL;

ADULT; AGED; ALLELE; ANALYSIS; ARTICLE; CANCER RISK; CASE CONTROL STUDY; CHEMOPROPHYLAXIS; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; GENE; HAPLOTYPE; HETEROZYGOTE; HIGH RISK POPULATION; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PANCREAS CANCER; PILOT STUDY; PRIORITY JOURNAL; RISK FACTOR; SAMPLE; SMOKING;

AGED; ALLELES; AMINO ACID SUBSTITUTION; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; GENETIC VARIATION; HAPLOTYPES; HETEROZYGOTE; HOMOZYGOTE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PILOT PROJECTS; POLYMORPHISM, SINGLE NUCLEOTIDE; PPAR GAMMA; RISK FACTORS; SMOKING;

EID: 68949092073     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e3181a53ef9     Document Type: Article

References (40)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-66.
2. Ghadirian P, Lynch HT, Krewski D. Epidemiology of pancreatic cancer: an overview. Cancer Detect Prev. 2003;27:87-93.
3. Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA. 1995;273:1605-1609.
4. Klein AP, Hruban RH, Brune KA, et al. Familial pancreatic cancer. Cancer J. 2001;7:266-273.
5. Silverman DT, Schiffman M, Everhart J, et al. Diabetes mellitus, other medical conditions and familial history of cancer as risk factors for pancreatic cancer. Br J Cancer. 1999;80:1830-1837.
6. Lynch HT, Smyrk T, Kern, et al. Familial pancreatic cancer: a review. Semin Oncol. 1996;23:251-275.
7. Lowenfels AB, Maisonneuve P, DiMagno EP, et al. Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. J Natl Cancer Inst. 1997;89:442-446.
8. Simon B, Printz H. Epidemiological trends in pancreatic neoplasias. Dig Dis. 2001;19:6-14.
9. Brand RE, Lynch HT. Genotype/phenotype of familial pancreatic cancer. Endocrinol Metab Clin North Am. 2006;35:405-415.
10. Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2005. US Department of Health and Human Services, Centers for Disease Control and Prevention. Atlanta, GA; 2005.
11. Gupta S, Vittinghoff E, Bertenthal D, et al. New-onset diabetes and pancreatic cancer. Clin Gastroenterol Hepatol. 2006;4:1366-1372.
12. Elbrecht A, Chen Y, Cullinan CA, et al. Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors gamma 1 and gamma 2. Biochem Biophys Res Commun. 1996;224:431-437.
13. Mukherjee R, Jow L, Croston GE, et al. Identification, characterization, and tissue distribution of human peroxisome proliferator - activated receptor (PPAR) isoforms PPARgamma2 versus PPARgamma1 and activation with retinoid X receptor agonists and antagonists. J Biol Chem. 1997;272:8071-8076.
14. Fajas L, Auboeuf D, Raspe E, et al. The organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem. 1997;272:18779-18789.
15. Lazar MA. PPAR gamma, 10 years later. Biochimie. 2005;87:9-13.
16. Sawai H, Liu J, Reber HA, et al. Activation of peroxisome proliferator - activated receptor-gamma decreases pancreatic cancer cell invasion through modulation of the plasminogen activator system. Mol Cancer Res. 2006;4:159-167.
17. Deeb SS, Fajas L, Nemoto M, et al. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet. 1998;20: 284-287.
18. Eftychi C, Howson JM, Barratt BJ, et al. Analysis of the type 2 diabetes-associated single nucleotide polymorphisms in the genes IRS1, KCNJ11, and PPARG2 in type 1 diabetes. Diabetes. 2004;53:870-873.
19. Savage DB. PPARgamma as a metabolic regulator: insights from genomics and pharmacology. Expert Rev Mol Med. 2005;2005:1-16.
20. Radha V, Vimaleswaran KS, Babu HN, et al. Role of genetic polymorphism peroxisome proliferator - activated receptor-gamma2 Pro12Ala on ethnic susceptibility to diabetes in South-Asian and Caucasian subjects: evidence for heterogeneity. Diabetes Care. 2006;29:1046-1051.
21. Moon MK, Cho YM, Jung HS, et al. Genetic polymorphisms in peroxisome proliferator - activated receptor gamma are associated with type 2 diabetes mellitus and obesity in the Korean population. Diabet Med. 2005;22:1161-1166.
22. Tavares V, Hirata RD, Rodrigues AC, et al. Association between Pro12Ala polymorphism of the PPAR-gamma2 gene and insulin sensitivity in Brazilian patients with type-2 diabetes mellitus. Diabetes Obes Metab. 2005;7:605-611.
23. Smith WM, Zhou XP, Kurose K, et al. Opposite association of two PPARG variants with cancer: overrepresentation of H449H in endometrial carcinoma cases and underrepresentation of P12A in renal cell carcinoma cases. Hum Genet. 2001;109:146-151.
24. Theodoropoulos G, Papaconstantinou I, Felekouras E, et al. Relation between common polymorphisms in genes related to inflammatory response and colorectal cancer. World J Gastroenterol. 2006;12: 5037-5043.
25. Fesinmeyer MD, Austin MA, Li CI, et al. Differences in survival by histologic type of pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:1766-1773.
26. Omenn GS. CARET, the beta-carotene and retinol efficacy trial to prevent lung cancer in high-risk populations. Public Health Rev. 1991;19:205-208.
27. Bowen DJ, Thornquist M, Anderson K, et al. Stopping the active intervention: CARET. Control Clin Trials. 2003;24:39-50.
28. Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med. 1996;334:1150-1155.
29. SeattleSNPS, NHLBI Program for Genomic Applications, Seattle, WA. Available from: http://pga.gs.washington.edu. Accessed July 15, 2005.
30. Barrett JC, Fry B, Maller J, et al. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21:263-265.
31. Schaid DJ. Evaluating associations of haplotypes with traits. Genet Epidemiol. 2004;27:348-364.
32. Sinnwell J, Schaid D, Yu Z. Statistical analysis of haplotypes with traits and covariates when linkage phase is ambiguous [haplo.design function in haplo.stats version 1.3.1]. 2007.
33. Wacholder S, Chanock S, Garcia-Closas M, et al. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst. 2004;96:434-442.
34. Koepsell TD, Weiss NS. Epidemiologic methods: studying the occurrence of illness. New York: Oxford University Press; 2003.
35. Street TO, Bradley CM, Barrick D. An improved experimental system for determining small folding entropy changes resulting from proline to alanine substitutions. Protein Sci. 2005;14:2429-2435.
36. Rowe A. Retinoid X receptors. Int J Biochem Cell Biol. 1997;29: 275-278.
37. McGrane MM. Vitamin A regulation of gene expression: molecular mechanism of a prototype gene. J Nutr Biochem. 2007.
38. Bairras C, Menard L, Redonnet A, et al. Effect of vitamin A content n cafeteria diet on the expression of nuclear receptors in rat subcutaneous adipose tissue. J Physiol Biochem. 2005;61:353-361.
39. Duell EJ, Holly EA, Bracci PM, et al. Population-based, case-control study of polymorphisms in carcinogen-metabolizing genes, smoking, and pancreatic adenocarcinoma risk. J Natl Cancer Inst. 2002;94: 297-306.
40. Anderson KE, Kadlubar FF, Kulldorff M, et al. Dietary intake of heterocyclic amines and benzo(a)pyrene: associations with pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:2261-2265.